470 million! Kyusju Tong has another big move

the | Ania National Pharmaceutical Holdings covers the largest number of level 3 hospitals, while Kyushua Tong has an advantage at the county and town level outlets, if the new crown vaccine vaccination sinks to the grass-roots level, Kyushua Tong will get more revenue.
on January 21, Kyushua Pharmaceutical Group Co., Ltd. (hereinafter referred to as Kyushuan) and the Asian Development Bank (ADB) and Germany Investment and Development Co., Ltd. (hereinafter referred to as Germany) signed a long-term loan agreement, and ADB and Germany issued a proposed joint 60 million euro (total 472 million yuan) private sector loan to Kyushua Tong for the expansion of Kyushua's pharmaceutical logistics center.
It is understood that this loan is intended to focus on Haikou City, Hainan Province, Tangshan City, Hebei Province and Nanjing City, Jiangsu Province, the construction and expansion of cold chain storage facilities, especially the construction, transformation and improvement of cold chain logistics facilities, will better improve Kyushua to pass on the vaccine and other cold chain biological products storage, distribution and service capacity.
in addition, Kyushua said: the most important measure to combat the new crown epidemic is to vaccinate the new crown vaccine, Kyushua to give full play to their advantages in the national cold chain logistics distribution and distribution, storage, system management and operation, the near-term focus on vaccine cold chain distribution services.
because of this year's special circumstances, once the vaccine is developed, vaccinations worldwide must be promoted in order to be truly immune.
In the case of repeated epidemic prevention at home and abroad, vaccine research and development and supporting facilities are the focus of social concern, in 2019 China's vaccine field issued a number of 580 million, this year's special circumstances brought about by the increase in the number of vaccines in 2.8-42 billion.
to some extent, the outbreak is a special event, if with the arrival of vaccines, the outbreak improved, vaccine demand declined, Kyusju to invest in the vaccine cold chain storage facilities will be how to deal with? In response to a question from Sebalan, Liu Zhaoying, vice chairman of Kyushua Tong, said: In order to meet the distribution of the new crown vaccine, Kyushua Tong has invested a lot of money - such as buying vehicles, hiring drivers, improving systems and operations, plus improving storage facilities in the cold chain.
these investments will also increase Kyusju Tong's business layout in the field of biomedicine.
, the demand for cold-chain logistics and distribution is growing year by year, including the need for cold-chain storage facilities and transportation for some testing reagents, said Liu Zhaoying, a professor at the Ministry of Health.
as a result, after the subsequent outbreak improved and vaccine demand declined, Kyusju Tong will move the new facilities to other biological products and vaccine products that require cold chains for transportation and storage.
the global biopharmaceutical market has grown from $129 billion in 2010 to $243 billion in 2018, with a compound annual growth rate of 8.24%, well above the 0.45% of traditional medicines, and the share of global drug sales has increased rapidly from 18% in 2010 to 28% in 2018, according to EvaluatePharma.
data show that China's biopharmaceutical market is still in its infancy, but has strong growth potential, ahead of the overall situation of the pharmaceutical market.
2018, China's biopharmace products market reached 262.2 billion yuan.
With increased affordability, patient population growth and expanded health insurance coverage, China's biopharmaceity market is expected to expand further to RMB641.2 billion by 2023, with a compound annual growth rate of 19.6% over the same period.
with increased investment in pharmaceutical research and development, the biopharmaceutical market is expected to reach RMB1,319.8 billion in 2030, with a compound annual growth rate of 10.9% from 2023 to 2030.
rapid growth of biopharmaceons has also accelerated its demand for cold-chain transportation.
Industry insiders told the financial community that China's biomedical cryogenic storage market industry growth rate is higher than the global (4.1%), under the new crown vaccine catalysis, the development of the cold chain transport industry is expected to speed up, and hundreds of millions of doses of calculated new crown vaccine, the cold chain market to bring huge imagination space.
To a certain extent, with the vigorous development of biopharmaceutical enterprises, the country's future support for further expansion, the market demand for cold chain logistics will also increase, so whether enterprises can use cold chain transport pharmaceutical products, whether the cold chain logistics qualifications put forward higher requirements.
It is worth noting that the transportation and preservation of pharmaceutical preparations has high professional requirements, especially vaccine products, need to have a very strong cold chain storage infrastructure support, which is often difficult to achieve ordinary logistics storage and cold chain, which is rich in cold chain logistics experience Kyusju Tong advantages.
Kyusju Tong benefit from the surge in demand for cold chains? It is understood that vaccine products, injection needles, antidoctures, oral drugs, foreign medicines, blood products and other pharmaceutical refrigeration products sales amount accounted for about 10% of the total sales of China's pharmaceutical circulation enterprises, the market space is huge.
the pharmaceutical cold chain has soared as a result of the increase in vaccines brought about by the outbreak.
, the market size of China's pharmaceutical cold chain industry grew from RMB750 million in 2013 to RMB1.24 billion in 2017, with a compound annual growth rate of 13.3%.
, according to the Panther Research Institute, the market size of China's pharmaceutical cold chain industry will reach 2.97 billion yuan by 2022.
Now, many enterprises have seen the business opportunities and market potential of the pharmaceutical cold chain - not only the main business for the pharmaceutical cold chain enterprises to enter the market, but also third-party logistics enterprises involved, and have greater competitiveness.
such as Shunfeng, with the establishment of the "cold transport division" in 2016, the main medical transport network currently covers 26 major cities in China, regional distribution covers 26 major cities around the 200 km area.
the same time, the state control, medicine, China Resources, Kyushua and other pharmaceutical circulation enterprises have been deployed pharmaceutical cold chain distribution business.
data show that Kyusju Tong company and its molecular companies have been carrying out pharmaceutical cold chain business for more than 20 years, has a wealth of cold storage resources, a total of 455 GSP cold storage, cold storage capacity of 105,000 m3, the accuracy of the storage rate of 99.999%.
in addition, Kyusju Tong has more than 250 refrigerated trucks and more than 5000 insulation boxes and other facilities and equipment, the company since 2014, set up a professional cold chain business division, the formation of more than 50 people of the pharmaceutical cold chain professional operation team, committed to vigorously develop cold chain business.
2019 annual report of Kyusju Tong disclosed that the company's cold chain support business in 2019 tax-inclusive sales of more than 3.6 billion yuan.
, compared with China National Pharmaceutical Holdings, it currently has 15 years of operating experience in the same national medicine, with more than 7,000 medical cold storage, medicine refrigeration vehicles nearly 60.
From the terminal coverage point of view, the state drug control covers the largest number of three-level hospitals, and Kyushua Tong in the county-level network has an advantage, if the new crown vaccine vaccination sinks to the grass-roots level, Kyushua Tong will get more revenue.
As Kyusju Tong said, the construction of cold chain logistics facilities will play an important role in ensuring that Kyusjutong better serves the emergency supply of medical supplies to a wider population, including china's second- and third-tier cities and rural areas.